[Clinical evaluation of cefdinir 10% granules in children]

Area of Science:

• Pediatric Infectious Diseases
• Clinical Pharmacology

Background:

• Cefdinir (CFDN) is an oral third-generation cephalosporin antibiotic.
• Bacterial infections in children require effective and safe treatment options.

Purpose of the Study:

• To evaluate the efficacy and safety of Cefdinir (CFDN) in pediatric patients.
• To assess the pharmacokinetic profile of CFDN in children.
• To compare the antibacterial activity of CFDN with other oral cephalosporins.

Main Methods:

• A total of 32 pediatric patients with various infections received CFDN at a daily dose of 6.4-19.8 mg/kg.
• Pharmacokinetic parameters including Cmax and T 1/2 were determined after a single 6.0 mg/kg dose.
• In vitro antibacterial activity against Staphylococcus aureus was assessed.

Main Results:

• CFDN demonstrated high efficacy, with a 94% success rate in treating respiratory tract, middle ear, urinary tract, and skin infections.
• The most common side effects were loose stool and diarrhea, occurring in 12.5% of patients.
• Pharmacokinetic studies showed a Cmax of 0.81 ± 0.38 μg/mL and a T 1/2 of 2.31 ± 0.77 hours.
• CFDN exhibited superior antibacterial activity against Staphylococcus aureus compared to other tested oral cephalosporins.

Conclusions:

• Cefdinir (CFDN) is a safe and effective option for treating common bacterial infections in children.
• The pharmacokinetic profile of CFDN supports its use in pediatric populations.
• CFDN's potent activity against Staphylococcus aureus makes it a valuable therapeutic choice.